Parkinson's Disease - Current Status and Challenges
Parkinson's disease is a progressive neurodegenerative disease in which dopamine-producing neurons in the brain are gradually lost. The disease is reported to affect approximately 1% of individuals aged 65 years and older.
Its primary symptoms include motor impairments such as tremor, rigidity, and bradykinesia (slowness of movement). As the condition progresses, non-motor symptoms also emerge, including depression, anxiety, cognitive impairment, and autonomic dysfunction, which significantly impact quality of life.
Current treatment focuses on dopamine-replacement pharmacotherapy and deep brain stimulation (DBS). While these provide temporary symptomatic relief, medication efficacy diminishes over time, and new side effects and challenges arise.
Furthermore, no treatment can halt the neurodegeneration itself, and non-motor symptoms are also not adequately addressed. There is an urgent need for novel therapeutic approaches that not only suppress symptoms but also address the progression of the disease itself.
A Novel Approach to the Treatment of Parkinson's Disease via Regenerative Therapy
Cellular Intervention Approach
In Parkinson's disease, dopaminergic neurons in the substantia nigra region of the brain degenerate and are lost. This cellular loss is the underlying cause that triggers motor impairments and various non-motor symptoms.
Conventional treatment only provides temporary symptomatic relief through dopaminergic medications (such as levodopa) and cannot regenerate lost neurons.
In response to this challenge, regenerative therapy utilizes stem cells, which has garnered significant attention in recent years.
Advances in Stem Cell Therapy for Parkinson's Disease
In the 1980s, experiments were conducted to transplant dopaminergic neural cells derived from fetal brain into patients. Although some effects were reported,
- Ethical concerns (societal anxieties regarding the use of fetal tissue)
- Low survival rate of transplanted cells
- Immune rejection
There are serious problems of this nature, and it has never been widely implemented.
Currently, research is evolving towards utilizing safer and more stable cell sources, with mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and neural stem cells gaining particular attention.
The Promise of Mesenchymal Stem Cells (MSCs)
MSCs are stem cells that can be extracted relatively easily from bone marrow, adipose tissue, and umbilical cord, and
- Possessing high proliferative capacity
- Can be induced to differentiate into neurons.
- Secretes cytokines that protect and repair damaged tissue.
Possesses such characteristics.
Especially in Parkinson's disease,the possibility of replacing lost dopamine neurons and improving the brain environment itselfIt has been shown, and in recent years, has become one of the most noteworthy approaches in the field of regenerative therapy.
Key Points
- The loss of dopaminergic neurons is the underlying cause of Parkinson's disease.
- Traditional medicine cannot regenerate the nerve itself.
- Stem Cell Therapy enables a fundamental approach to the replacement of lost nerve cells.
- Mesenchymal stem cells (MSCs) are potent therapeutic candidates, combining differentiation potential and protective effects.
How Stem Cell Therapy Works in Parkinson's Disease
Replenishing Lost Dopamine Neurons
It has been demonstrated that MSCs possess the ability to differentiate into dopaminergic neurons under appropriate conditions.
In experiments, when MSC-derived cells were transplanted into the brain, they extended axons and formed synapses, and are believed to contribute to the reconstruction of disrupted neural circuits by secreting dopamine.
By leveraging MSCs, not only neuroprotection but also the potential to replace lost neurons has become evident.
Protecting Damaged Nerves (Neuroprotective Effect)
MSCs, also referred to as "biofactories," secrete a wide range of beneficial cytokines and growth factors into their surroundings (e.g., BDNF, NGF, IGF-1, and others). In this manner,
- Promoting the survival of damaged neurons
- Promoting nerve repair and regeneration
- Soothing neural inflammation
It is hoped that this will demonstrate such neuroprotective effects and halt the progression of Parkinson's disease. In animal experiments utilizing umbilical cord-derived MSCs, an elevation in intra-cerebral IGF-1 was also accompanied by enhanced motor function and memory impairment.
Modifying the Brain's Intrinsic Environment
Exosomes secreted by MSCs contain substances with pro-angiogenic, antioxidant, and anti-apoptotic properties. These substances cross the blood-brain barrier to reach the brain.
- Formation of new capillaries
- Regeneration of the microenvironment (niche) surrounding nerve cells
- Inhibition of dopaminergic neuron cell death and restoration of dopamine concentration
Demonstrated in animal experiments, Stem Cell Therapy is not merely cell replacement but also an approach to re-engineer the brain as a field.
Key Points
- MSC differentiate into dopaminergic neurons and reconstruct lost neural tissue.
- Secretes abundant growth factors and promotes neuronal protection and repair.
- Calming chronic inflammation and enhancing the entire brain niche to a state conducive to neural regeneration
- A multi-faceted approach for the restoration of fundamental function in Parkinson's disease
The Perspective of Stem Cell Therapy in Improving Parkinson's Disease Symptoms
Effects Observed in Preclinical Research
At the basic research (preclinical) stage, MSC transplantation in animal models of Parkinson's disease (rats and mice) has demonstrated significant improvements in motor function and pathological findings.
- In models treated with umbilical cord-derived MSCs, a reduction in motor impairment, suppression of neuroinflammation, and increased survival of dopaminergic neurons were reported.
- Bone marrow-derived MSC transplantation also reduced dopaminergic neuron death in the substantia nigra, and a neuroprotective effect against neuronal damage was confirmed.
- Wharton's Jelly-derived MSCs were reported to demonstrate not only recovery of motor symptoms but also improvement in non-motor symptoms such as cognitive impairment and pain hypersensitivity.
Furthermore, studies reported that umbilical cord MSC transplantation restored BDNF (Brain-Derived Neurotrophic Factor) and NGF (Nerve Growth Factor) in the brain, and improvements in hippocampal synaptic plasticity (learning and memory function) were observed.
Expected Effects in Clinical Research
Human clinical trials have also yielded positive results, albeit on a smaller scale.
- In a recent systematic review, analyzing data from 9 trials involving 129 Parkinson's disease patients, the stem cell transplantation group demonstrated significant symptomatic improvement compared to the conventional treatment-only group.
- UPDRS (Unified Parkinson's Disease Rating Scale) scores significantly decreased in the transplant group, and the effect was reported to persist for at least 1 year.
- Specifically, umbilical cord MSCs are expected to provide superior effects owing to their youthful cellular state and high differentiation capacity.
Additionally, in one trial involving intracerebral transplantation of bone marrow-derived MSCs, with follow-up for up to 3 years, UPDRS scores improved by approximately 23% in the off-medication state and by approximately 38% in the on-medication state, and successful reductions in oral medication dosage were reported.
Future Prospects and Challenges
Admittedly, current clinical data are limited, and the case count is low. Nevertheless, it has progressed beyond the stage where effectiveness was considered unclear, and more robust evidence is anticipated to be gathered from ongoing global clinical trials.
It is now clear that Stem Cell Therapy for Parkinson's disease has becomeNew treatment option with clear potential for symptom improvement.
Key Points
- Preclinical studies have confirmed the protective effects on motor and neural function.
- In clinical trials, improvement in UPDRS scores and a trend towards symptom mitigation were observed.
- Umbilical cord MSCs, in particular, are highly promising given their youthful state and high differentiation capacity.
- It is anticipated that effectiveness will be further solidified through future large-scale trials.
Safety and Risk Assessment of Stem Cell Therapy for Parkinson's Disease
Research Report on the Safety of MSC Therapy
Notably, therapy utilizing allogeneic mesenchymal stem cells (MSCs) minimizes immune rejection reactions, and serious adverse events are rarely reported.
- In a clinical trial conducted in Parkinson's Disease patients, following intravenous injection of allogeneic MSCs, no donor-specific immune response (rejection) was detected, and high safety and tolerability were demonstrated.
- In a pilot study of autologous MSC transplantation into the brain, with follow-up extending up to 36 months, no tumor formation or serious adverse events were observed.
In this trial, positive biological changes were observed following cell administration, such as a decrease in inflammatory cytokines and an increase in neurotrophic factors (BDNF, IGF-1, etc.), as well as increased cerebral blood flow.
Common Side Effects and Risk Management
Side effects reported in MSC therapy are limited to temporary pain at the infusion site, fever, and mild headache. Compared to standard treatment, this treatmentevaluated as a very safe treatment.
Specifically, MSCs derived from Wharton's Jelly are sourced from newborns, exhibiting a high cell initialization rate and considered to have a low risk of genetic damage and aging.
The Importance of Healthcare Systems and Quality Management
Given that Stem Cell Therapy requires advanced medical technology,
- Rigorous infection control during cell culture
- Selection of the appropriate cell count and administration route
- Manufacturing and management in accordance with GMP standards.
Such comprehensive quality management and professional techniques are essential. Presently, this is safely executed in facilities compliant with these requirements, and further optimization is anticipated in the future.
Key Points
- In previous clinical trials, several serious adverse events associated with MSC treatment were reported.
- Low risk of immune rejection and high tolerance have been confirmed post-transplantation.
- MSC Wharton's Jelly, in particular, possesses a high potential for an excellent safety profile.
- By comprehensively implementing infection control and manufacturing quality, treatment can be provided more safely.
- Overall, MSC Stem Cell Therapy is a promising option with a high safety profile.
Novel Perspectives in Regenerative Therapy for Parkinson's Disease
Key Points
- In previous clinical trials, virtually no serious adverse events associated with MSC treatment were reported.
- Low risk of immune rejection and high tolerance confirmed post-transplantation.
- MSC Wharton's Jelly is particularly likely to offer safety advantages.
- By meticulously implementing infection management and manufacturing quality, treatments can be performed more safely.
- Overall, MSC Stem Cell Therapy is a promising option with a high safety profile.
Novel Perspectives in Regenerative Therapy for Parkinson's Disease
Novel Perspectives in Regenerative Therapy for Parkinson's Disease
Key Point
- To date, few serious adverse events associated with MSC therapy have been reported in clinical trials.
- 免疫拒絶リスクは低く、移植後も高い忍容性が確認されている
- Wharton's Jelly MSCs are particularly likely to demonstrate superior safety.
- 感染管理や製造品質を徹底することで、より安全に治療が行われている
- Overall, Mesenchymal Stem Cell Therapy is a promising option with a high safety profile.
パーキンソン病に対する再生医療の新たな展望
Previous treatment for Parkinson's Disease centered on "symptomatic therapy," which temporarily alleviated motor symptoms resulting from dopamine deficiency.
However, with the advent of regenerative therapy using stem cells, an approach that addresses the root of the problem, namely,replenishing missing dopamine neurons and reconstructing the brain's environment itselfIt has become real.
The research findings accumulated from animal experiments to human clinical trials provide solid support forsafety and efficacyStem Cell Therapy, and also gathering hope in the medical field.
For patients and families facing Parkinson's Disease, Stem Cell Therapy is becoming a presence that bringsA new, unprecedented choice and a sure hope..
- Rare Disease Information Center "Parkinson's Disease (Designated Rare Disease 6)" Disease Explanation (Prevalence: 1 in 100 people aged 65 and over)
Rare Disease Information Center - Xiong M, et al. "Replacing What Was Lost: A New Era of Stem Cell Therapy for Parkinson's Disease" (Review covering the challenges of fetal cell and iPS cell transplantation)
Translational Neurodegeneration - Wu K, et al. "Direct Comparison of Wharton's Jelly and Bone Marrow MSCs to Enhance Umbilical Cord Blood Transplantation" (Umbilical cord MSCs proliferate faster than bone marrow MSCs)
Biology of Blood and Marrow Transplantation - Prasanna SJ, et al. "Sitokin Pro-inflamasi, IFNγ dan TNFα, Mempengaruhi Sifat Imun MSC Sumsum Tulang Manusia dan Wharton Jelly secara Berbeda" (WJ-MSC memiliki immunogenisitas rendah bahkan di bawah rangsangan inflamasi)
PLOS One - Heris RM, et al. "Potential Use of Mesenchymal Stem Cells and Their Exosomes in the Treatment of Parkinson's Disease" (MSC differentiate into dopamine neurons and promote factor production)
Stem Cell Research and Therapy - Jalali MS, et al. "Therapeutic Effects of Wharton's Jelly-Derived MSCs on Behavior, EEG Changes, and IGF-1 in a Rat Model of Parkinson's Disease" (Umbilical cord MSCs show neuroprotection and cognitive improvement in a rat PD model)
Journal of Chemical Neuroanatomy - Zhao J, et al. "Efficacy of Stem Cell Transplantation in Patients with Parkinson's Disease: A Systematic Review and Meta-analysis" (Meta-analysis of 9 clinical trials confirmed UPDRS improvement)
Neurology Department - Venkataramana NK, et al. "Open-label Study of Autologous Bone Marrow MSC Transplantation in Parkinson's Disease" (Single-dose MSC transplantation; safe and effective at 36-month follow-up)
Translational Research - Levy YS, et al. "Allogeneic Bone Marrow MSCs – Safety in Idiopathic Parkinson's Disease" (A Phase 1 trial using allogeneic bone marrow MSCs confirmed safety)
Movement Disorders